What you should know:
1. Shai Friedland, MD, of Stanford (Calif.) Health Care, presented interim study results on the test’s effectiveness at the 2020 ASCO Virtual Scientific Program.
2. The study evaluated 354 patients with no prior history of CRC who received the blood-based test before having a colonoscopy.
3. The test detected CRC with 90 percent specificity and 100 percent sensitivity. It detected advanced adenomas with 75.5 percent sensitivity. Overall, the test boasts a 79.7 percent sensitivity rate for advanced adenomas and CRC.
4. The FightSight assay can detect three biomarkers in a patient.
More articles on healthcare:
14 ASCs opened or announced in July
Five COVID-19 updates for ASC leaders
Compass Surgical Partners hires executive administrator
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
